Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Curetis AG receives EUR 1.4 million investment


Press Release

A new investment enables Curetis AG to continue developing its molecular diagnostic platform for the fast and reliable diagnosis of infectious diseases

(Stuttgart/Holzgerlingen) The Swiss company aeris CAPITAL AG has invested EUR 1.4 million in the German molecular diagnostic company Curetis AG. The funding will allow Curetis to continue work on the development of its multiparameter molecular diagnostic platform. Curetis has thus successfully closed its first round of external funding which will increase total financing for Curetis to a total of EUR 2.5 million. At the same time, the privately held company has named Andreas Boos and Johannes Bacher as Managing Directors. Both bring extensive experience in the development of medical devices gained at previous positions with Hewlett-Packard, Agilent Technologies and Philips Medical Systems.

Curetis AG, which was founded in 2007, specialises in the development of molecular diagnostic solutions initially targeting severe infectious diseases such as tuberculosis. Both the company’s technology portfolios as well as the promising market potential were critical factors in the investment decision by aeris CAPITAL. “The Curetis team combines a long track record in clinical product development, market knowledge and a dynamic management with strong bio-assay development competences,” explained aeris CAPITAL partner Dr. Frank Mühlenbeck, who has joined Curetis' supervisory board as chairperson.

In addition, Curetis has been able to further strengthen its supervisory board with Hans-Günter Hohmann, who has over 30 years of experience in leading positions with Hewlett-Packard and Agilent Technologies in its global medical and analytical businesses. He started the diagnostic monitoring business, and was Vice President and the Managing Director of Agilent Technologies Germany. 'We are excited about the addition of Hans-Günter Hohmann, an acknowledged expert in international business operations, to our supervisory board,' stated Johannes Bacher, one of Curetis' Managing Directors. The Curetis' supervisory board is completed by Detlef Sasse, who held leading positions in Beckman Coulter for more than 30 years and priorto his recent retirement, was Vice President and Head of Commercial Operations in Europe, Africa, India and the near and far East. “The new supervisory board is a valuable asset for Curetis and will provide strong support in the area of investor relations, as well as in building and managing an international operation within the healthcare industry,” added Bacher.

Curetis is developing multiparameter diagnostic solutions initially focusing on combating severe bacterial infections. Globally, over 25 million people are diagnosed each year with life-threatening infections such as pneumonia, sepsis or tuberculosis. In the Western world, the annual economic burden associated with severe infections is estimated at over EUR 30 billion. Clinical experts as well as local and global healthcare organisations have expressed a strong demand for new, easy-to-use devices that allow the rapid detection of infectious agents and their potential resistance to antibiotics. The world-wide market potential for molecular microbiology is currently estimated at up to EUR 1 billion per year.

Curetis' Managing Director Andreas Boos recognised an additional market potential: “Technologically, our universal platform will undoubtedly be able to be applied to other disease areas. By focusing on multiparameter testing first, we believe Curetis will be able to position itself as a strong player in the field of molecular diagnostics. Thanks to the initial funding from aeris CAPITAL, we can now expand our operations to build a solid basis for product development, manufacturing and commercialisation.” Boos looks forward to a successful and close collaboration with aeris CAPITAL as lead investor to prepare for the next round of financing, in addition to the support from the company`s networks and organizations in the region.”We would like to thank BioRegio STERN for their substantial support over the last several months. They played a major part in the process which led to such a successful outcome.”


About BioRegio STERN:
BioRegio STERN Management GmbH is a skill-sharing network, providing a help and advice centre for founders of new businesses, entrepreneurs and researchers in the biotechnology sector in the region comprising Stuttgart, Tübingen, Esslingen, Reutlingen and Neckar-Alb in Germany. BioRegio STERN promotes cooperation between such different disciplines as medicine, biochemical engineering, sensor technology, dietetics, biochemical analysis and bioinformatics. Key areas of focus are regeneration biology, medical technology and bioenergy.

BioRegio STERN represents the interests of founders of new businesses, entrepreneurs and researchers when dealing with the political sector, the media and associations, coordinates economic promotional activities and marketing and provides advice for grant applications and corporate financing, all backed up with efficient press and public relations work.

BioRegio STERN is supported by the Stuttgart and Neckar-Alb regional authorities and the municipal authorities of Stuttgart, Tübingen, Esslingen and Reutlingen. The Managing Director, Dr. Klaus Eichenberg, is a molecular and cell biologist and investment analyst.

About Curetis
Curetis is a privately held molecular diagnostic company, which was founded in August 2007 and which focuses on the development and commercialisation of reliable, fast and cost-effective tools for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG will enable rapid multiparameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques. The analytical equipment is so simple and robust in its design that it can be used for ubiquitous molecular microbiology targeting. The universal platform will allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases.

Publisher: BioRegio STERN Management GmbH, Friedrichstrasse 10, 70174
Stuttgart, Germany, +49-711-8703540,
info@bioregio-stern.de
Editor: Zeeb Kommunikation GmbH, Hohenheimer Strasse 58a, 70184 Stuttgart,
Germany, +49-711-6070719, info@zeeb.info
Curetis AG: Dr. Anne Thews, Director Marketing & Sales, Max-Eyth-Straße 42,
71088 Holzgerlingen, +49-7031-49195-32, anne.thews@curetis.com


Publisher Contact Information:

Curetis
+49-7031-49195-32
anne.thews@curetis.com

Company profile of Curetis
Past press releases of Curetis.

Data


24,275
Tech investments
From our Online Data Service
15,691
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
May 18N/ABusiness applications
May 18€1.3MKnowledge management
May 18€9.1MInternet services
May 18€18.0MContent management
May 18€0.4MOther Computers & Electronics
May 17€51.0MeLearning
May 17€0.4MInternet services

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom

May 4
Vivet Therapeutics
vivet therapeutics raises €37.5 million in series a





About usContact usLegal Information
Copyright © 1999-2018
Emerging Technology Research Europe Inc. All rights reserved.